Concomitant Cephalosporins or Vancomycin During or After Treatment of Clostridioides difficile Infection Increases Risk of 3-Month CDI Recurrence

被引：0
|
作者：
Damianos, John [1 ]
Chaar, Abdelkader [2 ]
Rizwan, Rabia [2 ]
Mansoor, Muhammad Sohail [3 ]
Sharma, Prabin [4 ]
Malik, Umer Ejaz [5 ]
Alnahhas, Houssam [6 ]
Feuerstadt, Paul [1 ,7 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA
[3] GI Specialists Georgia, Marietta, GA USA
[4] NYU Langone Long Isl, Mineola, NY USA
[5] Albany Med Ctr, Albany, NY USA
[6] Syria Publ Hlth Network, London, England
[7] PACT Gastroenterol Ctr, Hamden, CT USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S207
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 35 条
  • [21] Comparison of outcomes after 3-month methadone maintenance treatment between heroin users with and without HIV infection: a 3-month follow-up study
    Wang, Peng-Wei
    Lin, Huang-Chi
    Yen, Chia-Nan
    Yeh, Yi-Chun
    Hsu, Chih-Yao
    Chung, Kuan-Sheng
    Chang, Hsun-Cheng
    Wu, Hung-Chi
    Yen, Cheng-Fang
    HARM REDUCTION JOURNAL, 2015, 12
  • [22] AN 8-STRAIN, RATIONALLY DEFINED BACTERIAL CONSORTIUM, VE303, REDUCES THE RISK OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI) RECURRENCE COMPARED WITH PLACEBO IN ADULTS AT HIGH RISK FOR RECURRENCE: RESULTS OF THE PHASE 2 CONSORTIUM STUDY
    Louie, Thomas J.
    Golan, Yoav
    Khanna, Sahil
    Ruthardt, Frederick W.
    Fratazzi, Candida
    Carini, Meg
    Ruisi, Mary
    Erpelding, Nathalie
    Li, Minran
    Bobilev, Dmitri
    Silber, Jeffrey L.
    Pardi, Darrell S.
    GASTROENTEROLOGY, 2022, 162 (07) : S21 - S21
  • [23] Identifying predictive features of Clostridium difficile infection recurrence before, during, and after primary antibiotic treatment
    Pakpour, Sepideh
    Bhanvadia, Amit
    Zhu, Roger
    Amarnani, Abhimanyu
    Gibbons, Sean M.
    Gurry, Thomas
    Alm, Eric J.
    Martello, Laura A.
    MICROBIOME, 2017, 5 : 148
  • [24] Identifying predictive features of Clostridium difficile infection recurrence before, during, and after primary antibiotic treatment
    Sepideh Pakpour
    Amit Bhanvadia
    Roger Zhu
    Abhimanyu Amarnani
    Sean M. Gibbons
    Thomas Gurry
    Eric J. Alm
    Laura A. Martello
    Microbiome, 5
  • [25] Substantial reduction of healthcare facility-onset Clostridioides difficile infection (HO-CDI) rates after conversion of a hospital for exclusive treatment of COVID-19 patients
    Ochoa-Hein, Eric
    Rajme-Lopez, Sandra
    Carlos Rodriguez-Aldama, Juan
    Asuncion Huertas-Jimenez, Martha
    Rosa Chavez-Rios, Alma
    de paz-Garcia, Roxana
    Haro-Osnaya, Anabel
    Karina Gonzalez-Colin, Karla
    Gonzalez-Gonzalez, Ricardo
    Fernanda Gonzalez-Lara, Maria
    Ponce-de-Leon, Alfredo
    Galindo-Fraga, Arturo
    AMERICAN JOURNAL OF INFECTION CONTROL, 2021, 49 (07) : 966 - 968
  • [26] A Risk Stratification Model for Cardiovascular Complications during the 3-Month Period after Major Elective Vascular Surgery
    Golubovic, Mladjan
    Stanojevic, Dragana
    Lazarevic, Milan
    Peric, Velimir
    Kostic, Tomislav
    Djordjevic, Miodrag
    Zivic, Sasa
    Milic, Dragan J.
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [27] Common Bacterial Infections during the 3-Month Period after SARS-CoV-2 Infection: A Retrospective Cohort Study
    Cohen, Bar
    Ben David, Shirley Shapiro
    Rahamim-Cohen, Daniella
    Nakhleh, Afif
    Shahar, Arnon
    Yehoshua, Ilan
    Bilitzky-Kopit, Avital
    Azuri, Joseph
    Reuveni, Miri Mizrahi
    Adler, Limor
    HEALTHCARE, 2023, 11 (24)
  • [28] IMPACT OF SER-109, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC, ON STOOL FATTY ACID METABOLITES IN A PHASE 3 RANDOMIZED TRIAL (ECOSPOR III) FOR TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)
    Bryant, Jessica A.
    Vulic, Marin
    Desjardins, Christopher
    Ford, Christopher B.
    Litcofsky, Kevin D.
    Wortman, Jennifer R.
    Henn, Matthew R.
    GASTROENTEROLOGY, 2022, 162 (07) : S21 - S21
  • [29] A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response
    Okhuysen, Pablo C.
    Ramesh, Mayur S.
    Louie, Thomas
    Kiknadze, Nino
    Torre-Cisneros, Julian
    de Oliveira, Claudia Murta
    Van Steenkiste, Christophe
    Stychneuskaya, Alena
    Garey, Kevin W.
    Garcia-Diaz, Julia
    Li, Jianling
    Duperchy, Esther
    Chang, Betty Y.
    Sukbuntherng, Juthamas
    Montoya, Jose G.
    Styles, Lori
    Clow, Fong
    James, Danelle
    Dubberke, Erik R.
    Wilcox, Mark
    CLINICAL INFECTIOUS DISEASES, 2024, 78 (06) : 1462 - 1472
  • [30] Efficacy and Safety of RBX2660 in Patients After First Recurrence of Clostridioides difficile Infection - Results From a Phase 3, Randomized, Placebo-Controlled Study
    Khanna, Sahil
    Tillotson, Glenn
    Ando, Masakazu
    Bancke, Lindy
    Harvey, Adam
    Garey, Kevin W.
    LaPlante, Kerry
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S138 - S138
1234